The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Parameters</td><td class="align_left"> </td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Patient number/eye</td><td class="align_center">31/35</td></tr><tr><td class="align_left">Mean age (year)</td><td class="align_center">50.66 ± 8.31</td></tr><tr><td class="align_left">Sex (male/female)</td><td class="align_center">23/8</td></tr><tr><td class="align_left">Baseline logMAR BCVA</td><td class="align_center">0.48 ± 0.26</td></tr><tr><td class="align_left">Baseline CMT (<i>μ</i>m)</td><td class="align_center">313.74 ± 144.5</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>CSC: central serous chorioretinopathy; logMAR: logarithm of the minimum angle of resolution; BCVA: best-corrected visual acuity; CMT: central macular thickness.<br/></div></td></tr></table>

<div>Baseline demographic and clinical characteristics of patients with chronic CSC treated with conbercept.</div>

Journal of Ophthalmology

tab1

Table 1

Table 1: The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy 